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Abstract  1 
 2 
Androgen signaling, via the androgen receptor (AR), is crucial in mediating prostate cancer 3 
initiation and progression. Identifying new downstream effectors of the androgens/AR 4 
pathway will allow a better understanding of these mechanisms and could reveal novel 5 
biomarkers and/or therapeutic agents to improve the rate of patient survival.  6 
We compared the microRNA expression profiles in androgen-sensitive LNCaP cells 7 
stimulated or not with 1 nM R1881, by performing a high-throughput RT-qPCR and found 8 
that miR-135a was up-regulated. After androgen stimulation, we showed that AR directly 9 
activates the transcription of miR-135a2 gene by binding to an androgen response element in 10 
the promoter region. Our findings identify miR-135a as a novel effector in androgens/AR 11 
signaling.  12 
Using xenograft experiments in chick embryos and adult male mice, we showed that miR-13 
135a overexpression decreases in vivo invasion abilities of prostate PC-3 cells. Through in 14 
vitro wound healing migration and invasion assays, we demonstrated that this effect is 15 
mediated through down-regulating ROCK1 and ROCK2 expression, two genes that we 16 
characterized as miR-135a direct target genes.  17 
In human surgical samples from prostatectomy, we observed that miR-135a expression was 18 
lower in tumoral compared to paired adjacent normal tissues, mainly in tumors classified with 19 
a high Gleason score (≥ to 8). Moreover, miR-135a expression is lower in invasive tumors, 20 
showing extraprostatic extension, as compared to intraprostatic localized tumors. In tumor 21 
relative to normal glands, we also showed a more frequently higher ROCK1 protein 22 
expression determined using a semi-quantitative immunohistochemistry analysis. Therefore, 23 
in tumor cells, the lower miR-135a expression could lead to a higher ROCK1 protein 24 
expression which could explain their invasion abilities. The highlighted relationship between 25 
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miR-135a expression level and the degree of disease aggressiveness suggests that miR-135a 1 
may be considered as a prognostic marker in human prostate cancer. 2 
  3 
4 
 
Introduction 1 
 2 
 Androgens play a pivotal role in initiation and progression of prostate cancer (PCa) (1-3). 3 
They function mainly by regulating target gene expression via the androgen receptor (AR) 4 
(4). AR acts as a ligand regulated transcription factor, which binds androgen response 5 
elements (ARE) in targeted genes. Localized PCa can be treated either by surgical resection or 6 
radiation therapy. For advanced or metastatic PCa, first-line therapeutic strategy is androgen 7 
deprivation associated with AR antagonists (5). Despite a good initial response, the disease 8 
progresses to a castration resistant prostate cancer (CRPC) (6, 7), which has limited 9 
therapeutic options and poor prognosis. A current challenge in PCa management is to 10 
understand the molecular mechanisms controlling disease progression (8).  11 
MicroRNAs (miRs) are small non-coding RNAs, acting as negative post-transcriptional 12 
regulators of protein-coding gene expression (9). MiRs interact by imperfect binding to 13 
specific-sequence located within the 3’ untranslated region (3’UTR) of targeted mRNAs, 14 
directing mRNA inactivation and/or translational repression. MiRs function as oncogenes 15 
(10) or tumor-suppressor genes (11, 12), can promote metastases spreading to distant sites 16 
(13, 14) and their deregulation is a common feature of human cancers initiation and 17 
progression (15). Moreover, miRs are already entering the clinic as diagnostic/prognostic 18 
indicators for patient stratification and as therapeutic strategies (12). 19 
Among deregulated miRs in PCa (16-19), some are under AR regulation (20-23). 20 
However, constructive analyses of the molecular mechanisms underlying such a regulation 21 
are lacking. MiRs working as effectors of androgens signaling might be biomarkers of 22 
prostatic tumor development, as well as therapeutic targets for innovative therapies.  23 
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Here, we identified miR-135a as an androgen up-regulated miR and investigated its 1 
mechanisms of action in PCa cells. Finally, we analyzed miR-135a expression in surgical 2 
samples and explored correlation with PCa progression.  3 
 4 
5 
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Results  1 
 2 
Identification of miR-135a as an androgen induced microRNA. 3 
To identify new androgen-regulated miRs in prostate cells, we performed a high-4 
throughput RT-qPCR analysis (Supplementary data 1) and compared the expression level of 5 
377 microRNAs in prostate androgen-sensitive LNCaP cells cultured for 2, 8, 24 and 48 hours 6 
in the presence or absence of 1 nM R1881. We observed that nine miRNAs were statistically 7 
up-regulated by androgens but only five (miR-135a, -135b, -193a-3p, -29a and -486-5p) were 8 
validated in a reproducible manner by RT-qPCR individual assays, in biological replicates. 9 
Finally, due to the greatest induction of its expression after androgen treatment, miR-135a 10 
was chosen for further investigation.  11 
As shown in Figure 1A, miR-135a expression increased after 8 h of androgen treatment (2 12 
fold over vehicle) to reach a 10 fold increase after 24 h. Moreover, R1881-induced miR-135a 13 
expression was reduced (-76.5%) in the presence of bicalutamide, an AR antagonist (Figure 14 
1B) and also following si-AR transfection (-70%; Figure 1C), strongly suggesting the 15 
involvement of AR in androgen-mediated regulation of miR-135a expression. Finally, the 16 
induction of miR-135a expression by R1881 was not affected in the presence of 17 
cycloheximide (Figure 1D), suggesting that the androgen-mediated miR-135a expression was 18 
directly induced by AR, without the requirement of intermediate protein factor synthesis. 19 
A similar androgen-induced miR-135a expression was observed, after 24 h of R1881 20 
treatment, in MOP and 22Rv1 cells, two other androgen-responsive prostate cell lines (22.8 21 
and 4.16 fold increase, respectively).  22 
 23 
 24 
 25 
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AR regulates miR-135a2 gene expression at transcriptional level.  1 
The mature miR-135a could be produced by two miR-135a genes in the human genome. 2 
MiR-135a1 and miR-135a2 are localized on chromosome 3 and 12, respectively. We analysed 3 
the expression of both genes after androgenic treatment by quantifying the amount of each 4 
pri-miR (Figure 1E) and observed that only pri-miR-135a2 expression was increased.  5 
A kinetic study revealed a rapid increase of pri-miR-135a2 expression within 1 h after 6 
androgen treatment. The fold induction increased until 12 h and then decreased while 7 
androgenic induction of mature miR-135a expression started after 6 h and rose until 24 h 8 
(Figure 1F).  9 
These data strongly suggest that the increased amount of mature miR-135a following 10 
androgen stimulation resulted from transcriptional activation of the miR-135a2 gene.  11 
 12 
Mechanisms of regulation of the miR-135a2 gene transcription. 13 
MiR-135a2 sequence is localized in an intron of the non-coding RMST gene (MI0000453, 14 
http://www.mirbase.org). However, this gene is not expressed in LNCaP cells (unpublished 15 
data), suggesting that miR-135a2 gene has its own transcriptional regulatory sequences. By 16 
5’RACE in LNCaP cells, we identified a transcription start site located 554 bp upstream of 17 
the first base of the pre-miR-135a2, which matches with the beginning of an Expressed 18 
Sequence Tag (EST, gb CA311800) (Figure 2A).  19 
As miR-135a was transcriptionally regulated by androgens via AR, functional AREs were 20 
searched within the miR-135a2 gene region. Using MatInspector software, we identified 21 
seven putative AREs in the 10 kb region upstream of the pre-miR-135a2 (Figure 2B). 22 
Transcriptional activities of three ARE-containing regions (-8800/-7600; -6740/-5500; -23 
1380/0) were tested in luciferase reporter assays. Only the construct containing the -6740/-24 
5500 fragment mediated activation (3.6 fold) of luciferase gene expression in response to 25 
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androgens (Figure 2C). This construct contains four potential AREs, termed ARE-2 to ARE-1 
5. Because the ARE-2 (caagtacagcttGTTCtcc), located at -5605 bp, is very close to the ARE 2 
consensus sequence (4), it was mutated (caagtaAagcttTTTCtcc) to check its role in androgen 3 
induction. As shown in Figure 2C, the induction of luciferase expression by R1881 was 4 
totally abolished by the mutation. Using chromatin immunoprecipitation (ChIP) with an AR 5 
specific antibody, we demonstrated in LNCaP cells a 4 fold increase of AR binding after 6 
R1881 stimulation onto the region containing ARE-2 (Figure 2D). Finally, these data suggest 7 
that miR-135a2 is a direct AR target gene. 8 
 9 
miR-135a directly targets ROCK1 and ROCK2. 10 
To explore the biological role of miR-135a, we searched for its putative target mRNAs. 11 
We performed a gene expression analysis in LNCaP cells overexpressing miR-135a versus 12 
cells transfected with miR negative control (miR-NC), using pangenomic microarrays. Details 13 
regarding the arrays are described in Supplementary data 2. In LNCaP cells overexpressing 14 
miR-135a, we identified 123 deregulated genes, mainly involved in cellular movement, 15 
cellular assembly/organization and cell morphology (Gene Ontology analyses), suggesting 16 
that miR-135a overexpression might affect these biological functions. Among the deregulated 17 
genes, 67 were down-regulated, 39 of which are potential direct targets containing 18 
complementary sequences of miR-135a seed box in their 3’UTR, as predicted by TargetScan. 19 
ROCK1, which encodes a Rho-associated kinase, belongs to these potential direct target 20 
genes. The second member of the ROCK family, ROCK2, (although not being listed as 21 
differentially expressed gene in microarray statistical analysis because of a hybridization 22 
defect on one of the two chip replicates), is implicated in same pathways and is also predicted 23 
to be a potential target gene (TargetScan). So, we focused our further analysis on ROCK1 and 24 
ROCK2, as potential targets of miR-135a.  25 
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We confirmed the effect of miR-135a overexpression on the down-regulation of ROCK1 1 
and ROCK2 expression, at mRNA and protein levels, by RT-qPCR and western blot analyses, 2 
respectively. LNCaP cells transfected with miR-135a mimics showed nearly 50% decrease in 3 
ROCK1 and ROCK2 mRNA levels (Figure 3A) and a dramatic decrease of ROCK1 and 4 
ROCK2 protein levels (up to 96% and 80%, respectively), as compared to control cells 5 
(Figure 3B). Next, we generated plasmids containing the 3’UTR of ROCK1 or ROCK2 6 
downstream of a luciferase gene (wt 3’UTR) and similar plasmids in which the sequences 7 
recognized by the miR-135a were deleted (mut 3’UTR) (Figure 3C). In HeLa cells co-8 
transfected with miR-135a mimics and wild type constructs, we observed a decrease in the 9 
luciferase activities (-57% and -32% for ROCK1 and ROCK2 constructs, respectively), as 10 
compared to pmirGLO empty vector (Figure 3D). In contrast, the expressions of the 11 
luciferase gene from mutant constructs were not affected by miR-135a overexpression. These 12 
data then revealed a direct interaction between miR-135a and 3’UTR of ROCK1 and ROCK2 13 
mRNAs. Altogether, these data confirm that ROCK1 and ROCK2 are specific direct targets 14 
of miR-135a.  15 
 16 
Androgens/AR signaling down-regulates ROCK1 and ROCK2 through miR-135a. 17 
In R1881-treated LNCaP cells, in which miR-135a expression was increased, we observed 18 
a strong decrease of ROCK1 and ROCK2 protein amounts (-74% and -65%, respectively; 19 
Figure 3E). The R1881-induced depletion of ROCK1 protein expression was blocked after a 20 
miR-135a inhibitor treatment (Figure 3E), suggesting that androgens down-regulate the 21 
expression of ROCK genes through miR-135a. 22 
 23 
 24 
 25 
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miR-135a inhibits in vitro cell migration and invasion by targeting ROCK1 and ROCK2.  1 
ROCK1 and ROCK2 proteins have been implicated in different cellular processes like 2 
migration and invasion. We then wondered whether miR-135a overexpression might 3 
modulate these cellular properties. We analysed the effect of miR-135a on cell behaviour 4 
using PC-3 prostate cells, which are endowed with migratory and invasiveness properties. 5 
In a wound healing migration assay, we observed that the speed of wound closure was 6 
significantly decreased in PC-3 cells overexpressing miR-135a (Figure 4A), suggesting that 7 
miR-135a has an anti-migratory action. In parallel, we artificially lowered the expression of 8 
the ROCK1 and ROCK2 proteins by co-transfecting siROCK1 and siROCK2 (siROCK1/2) or 9 
treating the cells with Y-27632, a chemical inhibitor of the ROCK kinases. These treatments 10 
also decreased cell migration, supporting the role of ROCK1 and ROCK2 in mediating the 11 
anti-migratory effect of miR-135a. To confirm this hypothesis, we co-expressed miR-135a 12 
and ROCK1 in PC-3 cells, which then recovered their migratory properties as compared to 13 
cells expressing miR-135a only. A further confirmation was brought when we looked at the 14 
phenotype of migrating cells. Cells transfected with miR-135a appeared elongated with 15 
multiple protrusions (Figure 4B), like siROCK1/2 transfected cells. Interestingly, forcing the 16 
expression of exogenous ROCK1 in cells overexpressing miR-135a restored a normal cell 17 
phenotype. All these data support then strongly the role of ROCK proteins in mediating the 18 
effects of miR-135a on cell migration. 19 
We further analysed the role of miR-135a in cell invasiveness. As shown in Figure 4C, 20 
overexpression of miR-135a as well as siROCK1, siROCK2 or treatment with Y-27632 21 
strongly decreased cell invasiveness. Here again, inhibition of cell invasiveness by miR-135a 22 
was abrogated by overexpressing ROCK1.  23 
 24 
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miR-135a overexpression inhibits in vivo tumoral cell invasion, in chick embryo and 1 
adult mouse. 2 
 To confirm the in vitro anti-invasiveness action of miR-135a, we investigated its effect in 3 
vivo, by using xenograft tumor experiments, in chick embryo and adult male murine models. 4 
We used PC-3 cells stably overexpressing either miR-135a or the miR-Null as control. 5 
A first xenograft experiment was performed by grafting modified PC-3 cells onto the 6 
chorioallantoic membrane (CAM) of 10 days chick embryos. At embryonic day 19, the 7 
developed tumors were recovered from the upper CAM and weighted. We did not observe 8 
any difference in embryo survival (80 versus 77.2%) or in tumor growth between the two 9 
groups of grafted embryos. We next counted the number of nodules in the lower CAM to 10 
assess the ability of the tumors to disseminate. An average of 3.071 (+ 1.016) nodules were 11 
counted in the lower CAM of PC-3 miR-Null grafted embryos, while an average of only 12 
0.852 (+ 0.718) nodules was counted in the lower CAM of PC-3 miR-135a grafted embryos 13 
(Figure 5A), suggesting that miR-135a inhibits the invasion ability of tumors.  14 
A second xenograft experiment was performed by injecting modified PC-3 cells 15 
subcutaneously into SCID mice. Interestingly, we observed, after 6 weeks, a strong difference 16 
in the localization of developed tumors between the two groups. All tumors that developed 17 
from PC-3 miR-135a cells showed a restricted subcutaneous localization and did not cross the 18 
peritoneum to invade the abdominal cavity. In contrast, all the tumors developed from PC-3 19 
miR-Null showed an evident penetration of the peritoneum. Representative images are shown 20 
in Figure 5B.  21 
These in vivo experiments clearly demonstrated that overexpressing miR-135a in the 22 
invasive PCa PC-3 cells efficiently inhibited their dissemination from the initial tumor, 23 
suggesting that miR-135a disrupts in vivo cell migration and invasion processes.  24 
 25 
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miR-135a expression decreases in tumoral compared to adjacent normal prostate tissues 1 
and with prostate cancer progression. 2 
To investigate the clinical value of miR-135a in PCa, we determined miR-135a expression 3 
level in 56 tumors and pair-matched adjacent normal tissues from prostatectomy 4 
(Supplementary Tables 2-3), by RT-qPCR.  5 
We found that miR-135a expression was significantly lower (p<0.0001) in tumor tissues 6 
than in paired normal tissues (Figure 6A). We then analyzed the relation between miR-135a 7 
expression and pathological grading. We observed a lower expression of miR-135a relative to 8 
paired normal tissue, in all the tumors classified with a high Gleason score (≥ to 8), compared 9 
to tumors with Gleason score ≤ to 7 (Figure 6B). We finally observed a significant decrease 10 
in miR-135a expression in invasive extraprostatic tumors (pT3a and b stages) as compared to 11 
intraprostatic localized tumors (pT2c stage) (Figure 6C), even if we could not separate 12 
seminal vesicle dissemination (pT3b stage) from non-seminal dissemination (pT3a stage) in 13 
extraprostatic group (Figure 6C). Therefore, the miR-135a expression level was inversely 14 
correlated with the pathological staging, precisely between localized and invasive tumors 15 
types.  16 
All these data suggest a decrease in miR-135a expression during PCa progression. 17 
 18 
ROCK1 protein expression is higher in tumoral compared to normal prostate glands. 19 
We next checked whether the ROCK1 expression might reflect miR-135a expression in 20 
prostate tumors. First, we determined ROCK1 mRNA expression level, by RT-qPCR, in the 21 
same samples in which we had previously determined miR-135a expression level. We did not 22 
observe any correlation between ROCK1 mRNA and miR-135a expression levels in these 23 
samples. Finally, immunohistochemistry analysis was performed on prostate sections 24 
containing both normal and tumor glands, from each of the 56 patients of the same cohort. 25 
13 
 
ROCK1 protein was revealed in both basal and glandular cells of glandular epithelium, and 1 
we observed more frequently a higher staining, corresponding to a higher ROCK1 protein 2 
expression, in tumor glands than in adjacent normal prostatic glands (Figure 6D). A semi 3 
quantitative analysis revealed a higher percentage of “high level” staining in tumor glands 4 
(29%) relative to normal glands (13%) (Figure 6E). In conclusion, ROCK1 protein 5 
expression seemed to be more frequently higher in tumor prostate tissue in which miR-135a 6 
expression was decreased. 7 
 8 
9 
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Discussion 1 
 2 
In the present study, we investigated the miRNome of LNCaP cells after androgenic 3 
stimulation, using microRNA Low Density Array profiling. We identified five significantly 4 
androgen up-regulated miRNAs, among which miR-135a showed the highest induction by 5 
androgens. Mir-193a-3p and miR-29a were previously reported as androgen induced miRs in 6 
LNCaP cells (20, 24) confirming the relevance of our approach.  7 
The expression of several miRs has been previously shown to be modulated by androgens 8 
in PCa cells (20, 21, 24-26). However, except for few of them (miR-21 (20); miR-27a (22); 9 
miR-32 and miR-148 (21)), the mechanisms of such androgenic regulation remain largely 10 
unexplored. A previously described ChIP-seq study identified an AR binding site in miR-11 
135a gene without specifying its localization or its functionality (21). In our study, we have 12 
shown that miR-135a androgen-mediated expression results from AR binding on a functional 13 
ARE upstream of the miR-135a2 gene. 14 
To explore the biological effects of miR-135a in prostate cells, we overexpressed miR-15 
135a in LNCaP cells and performed transcriptomic and in silico analyses. We identified 39 16 
down-regulated genes whose 3’UTR contains a complementary sequence to the miR-135a 17 
seed box. We focused on genes implicated in cell movement/morphology and organization 18 
processes (KCNMA1, KIF23, LCP1, NPC1, ROCK1 and ROCK2) and validated their 19 
microarray expression data by RT-qPCR analyses. For two of them, ROCK1 and ROCK2, we 20 
demonstrated that miR-135a interacts with their 3’UTR and down-regulates their expression, 21 
at mRNA and protein levels, attesting that ROCK1 and ROCK2 are miR-135a direct targets. 22 
ROCK1 and ROCK2 are implicated in actin cytoskeleton organization and actomyosin 23 
interaction, controlling thereby cell motility, adhesion and contraction (27, 28). Inhibition of 24 
15 
 
ROCKs has been shown to decrease in vitro migration and invasion ((29) and our present 1 
data) and in vivo dissemination of the invasive PC-3 cells (29).  2 
Taking these observations in account, we tested whether miR-135a could modulate these 3 
cellular processes in prostate cells. Using xenograft experiments, we showed that miR-135a 4 
overexpression inhibited in vivo PC-3 cell invasion in chick embryo and adult mouse. 5 
In addition, we demonstrated that the effect of miR-135a in decreasing PC-3 cell migration 6 
and invasion was mediated through ROCKs down-regulation. Similar results were obtained in 7 
HeLa cells (data not shown; (30)) and in gastric cells where miR-135a ability to suppress cell 8 
migration/invasion was also described to be mediated through ROCK pathway (31). In 9 
contrast, miR-135a has been reported to promote cell migration/invasion in other cell types 10 
like breast, colorectal and cervical cancer cells by targeting HOXA10 (32), MTSS1 (33) and 11 
SIAH1 (34) mRNAs respectively. 12 
We next investigated the clinical significance of miR-135a expression in PCa samples.  We 13 
observed that miR-135a expression level was significantly reduced in tumoral compared to 14 
pair-matched normal tissues, especially in patients with a high pathological grade, suggesting 15 
that miR-135a could be implicated in PCa progression. Moreover, miR-135a expression level 16 
decreases in invasive extraprostatic tumors (pT3) compared to intraprostatic localized tumors 17 
(pT2). As patients classified in pT3 stages relapse more quickly after chirurgical treatment 18 
(less than 5 years) than patients classified in pT2 stages, miR-135a might also be considered 19 
as a prognostic marker in PCa. We showed that miR-135a expression in androgen dependent 20 
(AD) LNCaP cell line is higher than in its androgen independent (AI) C4-2B and MOP 21 
sublines (data not shown); in the same way Ma et al have shown that miR-135a expression is 22 
lower in AI LNCaP-LNO versus LNCaP cells (35). As suggest by Wang et al (36), by using a 23 
computational approach combining microarray data, miR-135a could regulate the expression 24 
of genes influencing the progression of androgen-dependent to androgen-independent PCa. 25 
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Most of miRs up-regulated by androgens function as oncogenes, whereas miRs repressed 1 
by androgens function as tumor suppressors (20-22, 37-39). Interestingly, miR-135a 2 
expression is up-regulated by androgens and down-regulated in PCa cells, following a pattern 3 
identical to miR-29a (20, 40) and miR-Let7-c (41, 42). Moreover, miR-135a decreases the 4 
invasiveness of PC-3 cells, like miR-101 another androgen up-regulated miR (43).  5 
In tumor relative to normal glands, we showed a lower expression of miR-135a and a more 6 
frequently higher ROCK1 protein expression. As miR-135a expression level decreased, from 7 
low to high grade PCa, it could lead to an increase of ROCK1 expression and could explain 8 
an increase of tumor cell migration, invasion and metastasis dissemination.  9 
  10 
Links have been reported between androgens, AR and Rho/ROCK pathways: expression of 11 
RhoA, ROCK1 and ROCK2 are linked to AR expression level (44), androgens induce 12 
activation of RhoA and its translocation into the plasma membrane (45), RhoA has been 13 
recently identified as a direct AR-targeted gene (46) and Rho signaling has been involved in 14 
functional activation of AR (47). Interestingly, we have identified a novel way mediating the 15 
effects of androgens via AR in Rho signaling, through the regulation of miR-135a expression 16 
and its targets ROCK1/ROCK2. 17 
 18 
In conclusion, studying miR-135a and the whole panel of its target genes might identify 19 
novel potential biomarkers and alternative therapeutic strategies for survival improvement of 20 
patients with PCa. 21 
  22 
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Materials and Methods 1 
 2 
Cells. Human prostate (LNCaP and PC-3) and HeLa cells were cultured, as indicated by the 3 
ATCC. We generated PC-3 cells stably transfected with a pEGP-miR-Null vector (Cell 4 
biolabs) or a pEGP-miR-135a2 vector expressing a mature miR-135a. 5 
 6 
Androgen treatment. LNCaP cells were deprived of steroid during 48 h in phenol red-free 7 
RPMI 1640 medium supplemented with 5% charcoal filtered serum and treated with 1 nM 8 
R1881 (methyltrienolone, Perkin Elmer). For anti-androgen treatment, 10 µM bicalutamide 9 
(Astra Zeneca) was added to the medium 30 min before R1881 stimulation. To block protein 10 
synthesis, 25 µg/ml cycloheximide (Sigma-Aldrich) was added to the medium at the same 11 
time as R1881. 12 
 13 
RNA extraction. Total RNA was extracted from cells and tissue samples using TriPURE 14 
Isolation Reagent (ROCHE). 15 
 16 
Quantification of mature miR-135a by RT-qPCR. The reverse transcription (RT) reactions 17 
were performed, using TaqMan® microRNA RT Kit and TaqMan® small RNA primers 18 
assays (Applied Biosystems), with 200 or 10 ng total RNA for miR-135a or U6 snRNA, 19 
respectively. QPCR were performed with noUNG TaqMan® Universal PCR Master mix 20 
(Applied Biosystems). MiR-135a expression was normalized relative to U6 snRNA 21 
expression level. For tissue samples, RT reactions were performed with 10 ng total RNA and 22 
miR-135a expression was normalized relative to the RNU24 expression. Relative 23 
quantification was done using the 2-∆∆Ct formula.  24 
 25 
18 
 
Quantification of pri-miR and mRNA by RT-qPCR. cDNA was synthesized from 1 µg of 1 
total RNA treated with DNAseI, using the First-Strand cDNA Synthesis kit (Life 2 
Technologies). QPCR were performed using QuantiTect SYBR Green PCR kit (Qiagen) and 3 
primers listed in supplementary Table 1. Values were normalized by the median of 4 
housekeeping genes expression (TBP, RPS17, RPLP0; QuantiTect Primers, Qiagen). Relative 5 
quantification was done using the 2-∆∆Ct formula.  6 
 7 
5’RACE. RNA (1 µg) extracted from LNCaP cells with RNeasy mini kit (Qiagen) was used 8 
to determine the Transcription Start Site of pri-miR-135a2, using SuperscriptIII RT (55°C) 9 
and the 5’RACE system for rapid amplification of cDNA ends (Life Technologies, primers 10 
listed in supplementary Table 1). The PCR product was cloned by TA cloning in pGEM-11 
Teasy (Promega) and sequenced. 12 
 13 
Functional ARE identification by luciferase reporter assay. Fragments upstream of the 14 
miR-135a2 genomic location were amplified by PCR from LNCaP genomic DNA (primers 15 
listed in supplementary Table 1) and cloned into the pGL3-promoter vector (Promega). Two 16 
point mutations in the ARE-2 were inserted using the QuikChange II XL site-directed 17 
mutagenesis kit (Stratagene). Luciferase reporter assay was done, as previously described 18 
(48). 19 
 20 
Chromatin immunoprecipitation (ChIP). ChIP assay was done in LNCaP cells as 21 
previously described (48). Primers used for qPCR are listed in supplementary Table 1.  22 
 23 
miRNA, miRNA inhibitor, siRNA and plasmid transfections. miRNA mimics (50 nM 24 
miR-135a or miR-NC negative control#2; Applied Biosystems), pCAGmycROCK1 (a gift 25 
19 
 
from MF Olson) and pmirGLO were transfected into cells using Lipofectamine2000 (Life 1 
Technologies). siRNA anti-AR, anti-ROCK1, anti-ROCK2 or si-Non Targeting (si-NT) (50 2 
nM ON-TARGETplus SMARTpool, Dharmacon) and miR-135a inhibitor (25 nM miRCURY 3 
LNA Power Inhibitor, Exiqon) were transfected into cells using DharmaFECT (Dharmacon). 4 
 5 
Western Blot. 50 µg of proteins were analyzed by western blotting, using anti-ROCK1 6 
(GTX113266, 1:500, GeneTex), anti-ROCK2 (sc-1851, 1:200, Santa Cruz) and anti-β-tubulin 7 
(T4026, 1:4 000, Sigma-Aldrich) antibodies. Protein expression was quantified with 8 
MultiGauge software and normalized to β-Tubulin expression. 9 
 10 
Luciferase reporter assay for 3’UTR/miR interaction. The 3’UTR of human ROCK1 (nt 1-11 
920) and ROCK2 (nt 1-816) were amplified by PCR from LNCaP genomic DNA (primers 12 
listed in supplementary Table 1) and cloned downstream of the Firefly luciferase gene in the 13 
pmirGLO vector (Promega). The miR-135a binding sites were then deleted by PCR. 6 x 104 14 
HeLa cells seeded in 24-well plates were transfected with 200 ng of pmirGLO constructs and 15 
miRNA mimics. Two days later, cells were lysed and Firefly/Renilla luciferase activities were 16 
determined using the Dual Luciferase Assay System (Promega).  17 
 18 
Wound Healing migration assay. PC-3 cells were transfected with miRNA mimics, siRNA 19 
or treated with 16 µg/ml of Y-27632 (Sigma-Aldrich). Two days later, wounds were formed 20 
by scraping across cell monolayer using a micropipette tip. Phase contrast photomicrographs 21 
were recorded at 5 min intervals until 48 h, using a time-lapse microscope (Axiovert100M, 22 
Zeiss). The speed of wound closure was measured with ImageJ software. For ROCK1 rescue, 23 
2 µg of pCAGmycROCK1 were transfected 24 h after miRNA mimics transfection. 24 
 25 
20 
 
Matrigel invasion chamber assay. PC-3 cells were transfected with miRNA mimics, siRNA 1 
or treated with 16 µg/ml of Y-27632 and cultured 48 h in serum free medium containing 1% 2 
BSA. Cells were labeled 1 h at 37°C with 10 µg/ml DiIC12(3) (BD Biosciences) and seeded 3 
for 30 h into fluoroblock insert (8 µm pore size) with GFR (Growth Factors Reduced)-4 
Matrigel coated-membrane or not (BD Biosciences), placed in well containing 10% serum 5 
medium. Data were expressed as percentage of invasive relative to migrating cells. For 6 
ROCK1 rescue, 2 µg of pCAGmycROCK1 were transfected 24 h after miRNA mimics 7 
transfection. 8 
In ovo tumor growth and invasion assay. Work using chick embryos was done under 9 
animal experimentation permits N°381029 and N°B3851610001. Fertilized white Leghorn 10 
eggs were incubated at 38°C with 60% relative humidity for 10 days. At this stage (E10), the 11 
chorioallantoic membrane (CAM) was dropped by drilling a small hole through the eggshell 12 
into the air sac and a 1 cm2 window was cut in the eggshell above the CAM. PC-3 cells stably 13 
overexpressing miR-Null or miR-135a were labeled with VybrantTM DiO (Molecular 14 
Probes) and resuspended in serum free medium. For each condition, 106 cells (50 µl) were 15 
grafted onto the CAM of 35 embryos, before the eggs were returned to the incubator. At E19, 16 
the upper portion of the CAM was removed, transferred in PBS, then the tumors were cut 17 
away from normal CAM tissue and weighted. In parallel, a 1 cm2 portion of the lower CAM 18 
was collected and fixed in 4% formaldehyde in PBS to evaluate the number of invasive 19 
nodules, using a Leica Macrofluo fluorescent microscope.  20 
Xenograft studies in mice. Experiments were performed in compliance with the French 21 
Guidelines for care and use of experimental animals and approved by the ethical committee 22 
CECCAPP (C2EA-15) of the Ecole Normale Supérieure de Lyon. Stably genetically modified 23 
PC-3 cells (106 cells overexpressing miR-Null or miR-135a in 150 µl PBS) were injected 24 
21 
 
subcutaneously on the left flank of 8 weeks old male SCID mice. After 6 weeks post-1 
xenograft, animals were sacrificed by cervical dislocation, dissected and tumors collected.  2 
Human tissue samples. Prostate tissue with adenocarcinoma and normal adjacent counterpart 3 
were obtained from 56 patients who underwent radical prostatectomy. None of the patients 4 
had received preoperative chemotherapy or radiation therapy. Clinical informations for 5 
patients are summarized in supplementary Tables 2-3.  6 
 7 
Immunohistochemistry (IHC) on tissue samples. 3 µm-thick tissue sections were prepared 8 
from 56 paraffin embedded human prostate tissue samples. Immunohistochemical staining 9 
with anti-ROCK1 antibody (GTX113266, 1:80, GeneTex) was performed on the Ventana 10 
Benchmark Ultra XT automated stainer, using the ultraview DAB detection kit (Ventana).  11 
 12 
Statistical analysis. Statistical analyses were conducted using GraphPad Prism 5 software. A 13 
p-value < 0.05 was considered as statistically significant.  14 
  15 
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Legends to Figures 
Figure 1. Androgen regulation of miR-135a expression in LNCaP cells.  
Mature miR-135a expression or pri-miR-135a was quantified by RT-qPCR. Results are 
presented as the means + SD of three independent experiments.  
A. Kinetics of miR-135a expression in LNCaP cells treated with 1 nM R1881 compared to 
vehicle-treated cells. 
B. MiR-135a expression level in LNCaP cells treated with either 10 µM bicalutamide, 1 nM 
R1881 or both, relative to vehicle-treated cells. 
C. MiR-135a expression level in LNCaP cells, following 48 h transfection of 50 nM siRNA 
against AR (si-AR) or non-targeting siRNA (si-NT) and 24 h of 1 nM R1881 or vehicle 
treatment. 
D. MiR-135a expression in LNCaP cells treated with either 25 µg/ml cycloheximide, 1 nM 
R1881 or both, relative to vehicle-treated cells.  
E. Pri-miR-135a1 and 135a2 expression in LNCaP cells treated during 24 h with 1 nM R1881 
relative to vehicle-treated cells. 
F. Kinetics of pri-miR-135a2 and mature miR-135a expression in LNCaP cells treated with 1 
nM R1881 relative to vehicle-treated cells. 
 
Figure 2. Characterization of transcriptional regulation elements in miR-135a2 locus. 
A. Schematic illustration of miR-135a2 genomic region. The transcription start site (TSS), 
corresponding to the start of the pri-miR-135a2, was identified by 5’RACE and is represented 
by an arrow. The sequence of an Expressed Sequence Tag (EST), starting at the same location 
as TSS, was found in BLAST analysis and is represented flanked by two brackets. The 
sequences of the pre-miR-135a2 (underlined) and of the miR mature (surrounded) were 
recovered from miRBase with accession number MI0000453. 
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B. Schematic locations of the in silico-identified AREs upstream of the pre-miR-135a2. The 
sequence of the ARE-2 in grey circle is the closest to the ARE consensus sequence. 
C. Responsiveness to the ligand-stimulated AR of potential AREs identified upstream of the 
miR-135a2 locus assessed by luciferase reporter assays. HeLa cells were co-transfected with 
pSG5-hAR and pGL3-promoter constructs containing the potential AREs cloned upstream of 
the minimal promoter SV40. The ARE-2 is represented in grey. One construct contains an 
ARE-2 mutant represented by a grey barred circle. Cells were treated with 1 nM R1881 or 
vehicle for 24 h before harvesting for reporter analyses. Results are shown as luciferase 
activity in R1881 relative to vehicle treated cells and presented as the means + SD of three 
independent experiments.  
D. AR binding on ARE-2 region of miR-135a2 in LNCaP cells treated with 1 nM R1881 
relative to vehicle-treated cells and determined by chromatin immunoprecipitation (ChIP). 
LNCaP cells were treated or not with 1 nM R1881 during 24 h, ChIP experiments were 
carried out using an anti-AR antibody. The precipitated DNAs were used as templates for 
qPCR. As controls, promoter region of TBP served as non-target sequence while enhancer 
region of the PSA served as known AR target sequence.  
 
Figure 3. Androgens/AR signaling down-regulates ROCK1 and ROCK2 expression 
through miR-135a which binds to their 3’UTRs. 
A. ROCK1 and ROCK2 mRNAs expression in LNCaP cells, 48 h after 50 nM miR-135a or 
miR-NC (negative control) transfection and determined by RT-qPCR.  
B. Western Blot analysis of ROCK1 and ROCK2 protein expression in LNCaP cells, 48 h 
after 50 nM miR-135a or miR-NC transfection. The values below represent the relative 
abundance of the protein normalized to β-Tubulin expression.  
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C. Schematic representation of plasmid constructs containing ROCK1 or ROCK2 3’UTR 
with the putative sequences targeted by miR-135a (black square, complementary to the seed 
box) and the mutants deleted for miR-135a targeted sequence. 
D. Interaction of miR-135a with ROCK1 and ROCK2 3’UTRs assessed by luciferase reporter 
assay. The pmirGLO vectors containing wild type or mutant ROCK1 or ROCK2 3’UTR were 
transfected into HeLa cells with miR-135a or miR-NC. Results are presented as luciferase 
activity in miR-135a relative to miR-NC transfected cells. 
E. Western Blot analysis of ROCK1 and ROCK2 protein expression in LNCaP cells, treated 
during 48 h with 1 nM R1881 or vehicle (ethanol) and transfected or not at the same time with 
a miR-135a inhibitor. The values below represent the relative abundance of the protein 
normalized to β-Tubulin expression. 
For panels A and D, results are presented as the means + SD of three independent 
experiments.  
 
Figure 4. miR-135a decreases migration and invasion abilities via ROCK pathway. 
A. Time-lapse microscopy analysis of cell migration. PC-3 cells, transfected with either miR-
NC, miR-135a, siROCK1 and siROCK2 (siROCK1/2) or miR-135a and ROCK1 cDNA or 
treated with Y-27632 were analysed by video-microscopy in wound healing assays. In the 
upper panel, the speed of wound closure was expressed as percentage relative to the one in 
miR-NC transfected cells. In the lower panel, representative pictures of wound closure are 
presented (Bar = 100 µm). 
B. Morphology of migrating PC-3 cells. Microscopy images of PC-3 cells transfected with 
either miR-NC, miR-135a, siROCK1 and siROCK2 (siROCK1/2) or miR-135a and ROCK1 
cDNA or treated with Y-27632. The white arrows show cells with protrusions. Bar = 50 µm. 
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C. Matrigel invasion assay on PC-3 cells transfected with either miR-NC, miR-135a, 
siROCK1, siROCK2 or miR-135a and ROCK1, or treated with Y-27632. In the left panel, the 
percentage of invasive cells (determined as described in material and methods) was expressed 
relative to the one in miR-NC transfected cells. In the right panel, representative pictures of 
cells invading through matrigel under some conditions (Bar = 100 µm). 
 
Figure 5. miR-135a overexpression inhibits in vivo invasion abilities of prostate PC-3 
cells. 
A. Quantification of nodules observed in the lower chorioallantoic membrane (CAM) of chick 
embryos grafted with miR-Null or miR-135a overexpressing PC-3 cells. Fluorescent labeled 
PC-3 cells stably overexpressing miR-Null or miR-135a were grafted onto the CAM of 10 
days chick embryos (E10). At E19, a quantification of fluorescent nodules observed in the 
lower CAM was done. Columns represent the average number of nodules per egg; error bars 
represent standard deviations; n, number of grafted embryos who are alive at E19;  ****, p-
value < 0.0001.  
B. Representative images showing the intraperitoneal or subcutaneous localization of tumors 
developed in mice grafted with miR-Null or miR-135a overexpressing PC-3 cells, 
respectively. PC-3 cells stably overexpressing miR-Null or miR-135a were subcutaneously 
injected in the left flank of 8-weeks adult male SCID mice. After 6 weeks, animals were 
dissected and tumors photographed. n, number of mice who developed tumors.  
 
Figure 6. miR-135a expression decreases with prostate cancer progression. 
A. MiR-135a expression in 56 tumor and adjacent normal tissues from prostatectomy was 
determined by RT-qPCR. Statistical analysis was performed according to the Wilcoxon 
matched-pairs signed-ranks test. ****, p<0.0001. 
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B. miR-135a expression, determined by RT-qPCR, in 56 PCa samples (in tumor relative to 
paired normal tissue from the same patient) in correlation with the Gleason score. Statistical 
analysis was performed by an unpaired t-test with Welch’s correction. **, p<0.01 
C. miR-135a expression, determined by RT-qPCR, in 56 PCa samples (in tumor relative to 
paired normal tissue from the same patient) in correlation with the pathological stage. pT2c, 
cancer localized within the prostatic capsule; pT3a, cancer extension outside the prostate but 
without seminal vesicles (SV) invasion; pT3b, cancer extension outside the prostate with SV 
invasion. Statistical analyses between groups were performed using an ANOVA analysis and 
between each group by Tukey-Kramer’s Multiple Comparison test. ns, non-significant; *, 
p<0.05; **, p<0.01. 
D. IHC experiments were done on 56 prostate samples from patients with PCa to determine 
ROCK1 protein expression level. A representative picture was taken at 400 x magnification. 
ROCK1 staining is given by a DAB brown stain. N, normal gland; T, tumor gland.  
E. ROCK1 IHC experiments were done on 56 prostate samples from patients with PCa. 
ROCK1 protein expression was evaluated by a semi-quantitative IHC analysis. ROCK1 
staining was rated as “high”, “medium” or “low” and percentage of normal or tumor glands 
with high, medium or low ROCK1 protein expression determined. 
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